Merck & Co. Inc.’s efforts to reinvent its R&D business and rebuild its reputation as a research-based pharmaceutical company will be tested over the next year, as the company begins to see the results of the overhaul started just six months ago.
The company used a May 6 investor meeting to present the firm’s realigned R&D and commercial strategies, which strongly emphasize...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?